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Abstract
Heparanase is an endo-β-glucuronidase that specifically cleaves heparan sulfate proteogly-
cans in the extracellular matrix. Expression of this enzyme is increased in several pathologi-
cal conditions including inflammation. We have investigated the role of heparanase in
pulmonary inflammation in the context of allergic and non-allergic pulmonary cell recruit-
ment using heparanase knockout (Hpa-/-) mice as a model. Following local delivery of LPS
or zymosan, no significant difference was found in the recruitment of neutrophils to the lung
between Hpa-/- and wild type (WT) control. Similarly neutrophil recruitment was not inhibited
in WT mice treated with a heparanase inhibitor. However, in allergic inflammatory models,
Hpa-/- mice displayed a significantly reduced eosinophil (but not neutrophil) recruitment to
the airways and this was also associated with a reduction in allergen-induced bronchial
hyperresponsiveness, indicating that heparanase expression is associated with allergic re-
actions. This was further demonstrated by pharmacological treatment with a heparanase in-
hibitor in the WT allergic mice. Examination of lung specimens from patients with different
severity of chronic obstructive pulmonary disease (COPD) found increased heparanase ex-
pression. Thus, it is established that heparanase contributes to allergen-induced eosinophil
recruitment to the lung and could provide a novel therapeutic target for the development of
anti-inflammatory drugs for the treatment of asthma and other allergic diseases.
Introduction
Heparan sulfate proteoglycans consist of a protein core decorated with heparan sulfate linear
polysaccharides. This family includes syndecans, glypicans and secreted forms of extracellular
matrix proteoglycans (e.g. perlecan). Heparan sulfate can bind to a range of proteins (e.g.
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chemokines, growth factors, growth factor receptors) and thereby fine tune signaling within
the extracellular matrix [1,2]. Manipulating the expression pattern of these proteoglycans high-
lights the critical role of these macromolecules in growth and development, tissue injury and
repair, cell signaling, extracellular matrix barrier function and tumor metastasis. For example,
mice deficient in heparan sulfate proteoglycan are embryonically lethal [3], whilst mice defi-
cient in perlecan have impaired angiogenesis and reduced wound healing [4]; syndecan-1 is
also implicated in wound healing and angiogenesis [5,6]. However, few studies have examined
the role of heparan sulfate proteoglycans in pulmonary inflammation. Mice deficient in synde-
can-1 were associated with an increase in eosinophil recruitment to the airways and bronchial
hyperresponsiveness, whilst soluble forms of syndecan-1 administered to allergic mice were
protective [7]. Syndecan-1 also binds to neutrophil elastase and promotes an inflammatory mi-
lieu [8].
Mammalian heparanase is an enzyme that specifically cleaves heparan sulfate chains. This
enzyme was first cloned in 1999 and is the only known mammalian enzyme capable of disas-
sembling heparan sulfate [9,10] and is expressed in many inflammatory cells including dendrit-
ic cells, T and B cells, platelets, macrophages, neutrophils and mast cells and is implicated in
mediating diapedesis and recruitment of leukocytes to inflammatory sites [11]. Increased ex-
pression of heparanase in various tumours correlates with tumour invasiveness, angiogenesis
and poor prospective survival. There is also evidence of increased heparanase expression in in-
flammatory bowel disease [12] and in the synovium of rheumatoid arthritis patients [13].
Heparanase overexpression in mice led to an exacerbation of delayed type hypersensitivity
(DTH) reaction in the skin [14] and may specifically regulate transmigration of monocytes in
this inflammatory response [15]. Few studies have examined the role of this enzyme in regulat-
ing pulmonary recruitment of inflammatory cells. This is relevant to an understanding of the
pathophysiology of inflammatory diseases like asthma and COPD which are characterized by
the presence of inflammatory cells like eosinophils and neutrophils. It has been reported that
mice deficient in heparanase are protected from sepsis-induced acute lung injury [16] and al-
lergic inflammation [17], suggesting that heparan sulfate provides a pro-inflammatory cue.
However, elimination of syndecan-1 appears to lead to an exacerbation of the allergic inflam-
matory response [7]. Hence, we hypothesize that heparanase could play a role in inflammatory
cell migration in lung inflammation and used heparanase knockout (Hpa-/-) mice and pharma-
cologically treated mice as two models to investigate the role of heparanase in pulmonary in-
flammation and changes in pulmonary lung mechanics.
Methods
Human lung tissue
Lung tissue from human subjects (anonymized) was obtained from the National Jewish Health,
Denver USA (normal controls) and from the Lung Tissue Repository Consortium (COPD
lungs) [18] and tissue heparanase expression was detected using a previously described method
[19].
Lung samples were obtained either from surgical lung biopsy or explants at the time of lung
transplantation. Severity of COPD was stratified according to the 2013 Global Initiative for Ob-
structive Lung Disease (www.goldcopd.com) guidelines, which ranged from Stage 0 (normal
spirometry with chronic symptoms), Stage I (FEV1/FVC < 70% with FEV1> 80% predicted),
Stage II (FEV1/FVC < 70% with FEV1 50–79% predicted), Stage III (FEV1/FVC < 70% with
FEV1 30–69% predicted), and Stage IV (FEV1/FVC< 70% with FEV1< 30% predicted). Sam-
ples were de-identified, and banked samples obtained via, and approved by, the Colorado Mul-
tiple Institutions Review Board (number 08–1462). We performed immunofluorescence on 4-
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μm paraffin-embedded sections using a rabbit polyclonal antibody to human heparanase (Pro-
spec, Ins-26-2, 1:1000). Rabbit IgG (Abcam, 27472, 1:1000) served as an isotype control. We
measured intensity of staining using Metamorph (Molecular Devices, Sunnyvale, CA), as previ-
ously described [19].
Animal Welfare and Maintenance
Female BALB/c mice (18-20g; Charles River or Harlan, UK) were housed in rooms maintained
at a constant temperature (21 ± 2°C) and humidity (55 ± 15%) with a 12 hour light-dark cycle.
Animals had food (SDS, UK) and water available ad libitum. All experiments were performed
under The Scientific Procedures (Animals) Act 1986 and a Home Office project licence (PPL
70/8021) approved by the Animal Welfare and Ethical Review Board at King’s College London.
Studies using mice deficient in heparanase [20] were carried out at the Department of Medical
Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden and approved by Upp-
sala Ethical Committee on Animal Experiments (ethical approval number; C228/12 and C135/
8). Animals had free access to food and water and were housed with suitable enrichment and
bedding with 12h day/night cycle. All surgery was performed under general anaesthesia
(King’s College London, urethane; Uppsala University, pentobarbital sodium) and all efforts
made to minimize suffering.
Induction of non-allergic airway inflammation
In order to establish lung inflammation, mice were anaesthetised with isoflurane and dosed in-
tranasally (i.n.) with either zymosan (4 mg/kg) (Sigma-Aldrich, UK) or LPS (1.25 mg/kg)
(from Escherichia Coli, Sigma-Aldrich, UK). Control mice received the same volume (i.n) of
sterile saline.
Induction of allergic airway inflammation
For pharmacological studies, allergic airway inflammation was induced in WT BALB/c mice.
In these studies, mice (6–8 weeks) were sensitised with ovalbumin (OVA, i.p.) (Chicken oval-
bumin, grade V. Sigma, UK). Each mouse received 30 μg of OVA absorbed in 16 μL of alumini-
um hydroxide (Ems, Brazil) in saline to give a final volume of 0.4 mL. Sham mice received
saline and aluminum hydroxide alone. Control and OVA mice were sensitised on day 1 and
boosted on days 7 and 14. On days 21–23 (BAL) or 21–24 (lung function), OVA-sensitised
mice were exposed to 3% OVA by aerosol in a small chamber attached to a nebuliser (DeVill-
bisS 99; HCE, UK). On each challenge day mice were exposed to OVA for 30 minutes (Fig 1A).
In a separate series of experiments, allergic airway inflammation was induced in Hpa-/- mice
backcrossed for more than 10 generations to the C57BL/6J genetic background [20]. Experi-
mental groups were age and sex matched (WT control: 6♀, 5♂; WT OVA: 7♀, 5♂; Hpa-/-
control: 5♀, 2♂: Hpa-/- OVA: 5♀, 4♂) andWT littermates were used as controls. In these ex-
periments, mice (10–14 weeks) were immunized i.p. with 10 μg of OVA (Sigma-Aldrich) in
100 μl of PBS on days 1, 3, 6, 8, 10, 13 and 15. Control mice were non-immunized. On days 31,
34 and 36, mice were anaesthetized with isofluorane (4%) for intranasal administration with
20 μg of OVA in 20 μL of PBS (Fig 1B).
Pharmacological intervention
Mice were subcutaneously (s.c.) administered with the heparanase inhibitor (Muparfostat, PI-
88; 30 – 100 mg/kg: Progen Pharmaceuticals, Brisbane Australia) or vehicle either once (q.i.d.)
or twice (b.i.d.) a day in the non-allergic model or daily in the case of the allergic inflammatory
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model. In the case of allergic studies, animals were treated on 3 (eosinophil recruitment) or 4
(lung function) consecutive days.
Assessment of Lung Function
Animals were anaesthetised with urethane (2 g/kg) i.p. 24 hours after the last OVA challenge
and lung function was measured using a previously described technique [21]. A tracheotomy
was performed and a cannula inserted and sutured in place. Mice were then placed in a plethys-
mograph chamber via the cannula connected to a 4-way manifold with one port attached to a
differential pressure transducer (± 20 cm H2O: Validyne, UK). Two ports were connected to
the inspiratory and expiratory ports of a volume cycled ventilator (CWA Incorporated, USA).
Mice were ventilated at 150 breaths/minute with a tidal volume of 0.15–0.20 mL and a positive
expiratory pressure between 3 and 5 cm H2O. Transpulmonary pressure was estimated as the
difference between mouth pressure and box pressure, as the chest wall contributes little to the
overall compliance of the respiratory system. Changes in flow were determined with a Fleisch
pneumotachograph connected to a side port of the chamber. Flow was measured with a dif-
ferential pressure transducer (± 20 cm H2O: Validyne, UK). The flow was recorded to give a
continuous reading of tidal volume. Breath-by-breath recording of total lung resistance (RL:
cmH20.s/L) was calculated by an online respiratory analyser on a computer (LFR 7; Mumed
Ltd., UK).
Airway responsiveness was assessed by inhaled aerosolised methacholine at a concentration
range of 3.125–50 mg/mL. Aerosols of methacholine generated from an ultrasonic nebulizer
were administered directly to the lungs via the cannula and a port of the plethysmograph.
Aerosolised solutions were delivered to the mouse for 8 seconds, at a rate of 150 breaths/minute
with a tidal volume of 0.15–0.2 mL. Total airway resistance was measured prior to, and follow-
ing administration of saline and then following administration of methacholine. Upon comple-
tion of experiments, animals were humanely killed by cervical dislocation. The provocative
concentration (PC) of methacholine which caused a 100% increase in post saline RL (RL
PC100) and peak response (i.e. maximum percentage change in post saline RL) for each animal
was used as a measure of airway sensitivity and reactivity, respectively.
Fig 1. Protocol for allergen sensitization and challenge. Diagrammatic representation of the sensitization
and challenge protocols to induce allergic lung inflammation in WT BALBc (A) and Hpa-/- (B) mice. Arrow
represents exposure to ovalbumin (OVA). Biological readouts were undertaken 24 h following the last OVA
administration. In (A), bronchoalveolar lavage and lung function was measured on day 24 and day 25
respectively. In (B), BAL and serum samples were collected on day 37.
doi:10.1371/journal.pone.0127032.g001
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BAL fluid analysis
Mice were humanely killed 24 h after receiving the inflammatory stimulus with an intraperito-
neal (i.p) injection of 0.2 mL 50% urethane (King’s College London) or 40 – 60 mg/kg pento-
barbital sodium (Uppsala University). Lungs were lavaged via a cannula inserted into the
trachea and instilled with 3 x 0.5 mL of sterile saline (King’s College London) or with 2 x 1 mL
of sterile HBSS (Uppsala University). In experiments using Hpa-/- allergic mice, BAL fluid anal-
ysis was performed as previously described [22]. For differential cell counts, cytospin slides
were prepared using 150 μL of BAL fluid spun at 1000 x g for 1 minute. Cytospins were allowed
to dry before staining using a Diff-Quick stain. Differential cell counts were performed accord-
ing to standard morphological criteria on Diff-Quick stained cytospins (100 cells/sample).
Cells were identified as mononuclear cells, neutrophils and eosinophils. Almost all mononucle-
ar cells observed were macrophages, but for accuracy and clarity of presentation, were analyzed
and analysed as mononuclear cells. To perform total cell counts, 50 μL of BAL fluid was mixed
well with 50 μL of Türk solution (Merck, Germany) and counts performed using a haemocyt-
ometer. The total number of cells counted was then standardised to the number of total cells x
106/mL. In both instances, the individual counting the cells was blind to treatment
or genotype.
IgE ELISA
IgE anti-OVA ELISA were performed as previously described in allergic WT and Hpa-/- mice
[22]. For analysis of OVA-specific IgE in sera, 96-well microtiter plates (Nunc) were incubated
overnight at 4°C with goat anti-mouse IgE coating antibody (10 μg/mL, 100 μL) from the
Mouse IgE ELISA Quantification Kit (Bethyl Laboratories). Plates were washed three times
with 200 μL washing buffer (50 mM Tris, 0.14 M NaCl, 0.05% Tween-20, pH 8) and then incu-
bated with 200 μL blocking buffer (50 mM Tris, 0.14 M NaCl, 1% BSA, pH 8) for 2 h in room
temperature. Mouse sera were diluted 1:3 in blocking buffer and incubated for 2 h (100 μL).
Plates were washed and bound anti-OVA antibodies were quantified by first incubating with
biotinylated OVA (2 μg/mL, 100 μL) for 60 minutes. Plates were then washed five times before
adding strepavidin-peroxidase conjugate (0.05 U, 100 μL, Roche Diagnostics) and incubating
for 30 minutes. After five washes, 3,30,5,5’-tetramethylbenzidine liquid substrate (100 μL,
Sigma-Aldrich) was added. The reaction was stopped after 30–45 minutes by adding 100 μl 2M
H2SO4 and plates were read at 450 nm.
In the biotinylation procedure 10 mg OVA (Grade V, Sigma-Aldrich) in 1 mL PBS was
mixed with 2.5 mg biotinamidocaproic acid 3-sulpho-N-hydroxy-succinimide ester (Sigma-Al-
drich) dissolved in 0.25 mL distilled water. The mixture was stirred for 2 h at room tempera-
ture. To remove unreacted biotin the mixture was dialysed against PBS at 4°C and then the
biotinylated OVA was stored at 4°C in 0.1% sodium azide.
Statistical Analysis
Data was expressed as median, with interquartile range unless otherwise specified. Cell data
was analyzed using non-parametric methods (Kruskal Wallis, and MannWhitney U test). In
some instances, neutrophil or eosinophil recruitment to the lung was expressed as a percentage
in terms of the average number of total cells. Analysis of variance with Dunnett’s post hoc test
was used to analyze RL PC100 (log transformed) and peak response in RL. Data was analyzed
using GraphPad Prism version 5. P values of< 0.05 were considered to be significant.
Heparanase and Airway Inflammation
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Results
Non-allergic inflammation in Hpa-/- mice
Zymosan induced inflammation. The total number of cells in the BAL fluid of saline in-
jected WTmice (median, 25–75 percentile; 0.72 (0.60 – 0.96) x 106 cells/ml, n = 5) was pre-
dominantly comprised of mononuclear cells and represented 99% of the total cell population
with an absence of neutrophils. There was a significant increase in total number of cells (Fig
2A, p = 0.038) and neutrophils (Fig 2B, p = 0.0016) recruited to the airways following challenge
with zymosan. There was no significant difference in the number of total cells (Fig 2A) or neu-
trophils (Fig 2B) between Hpa-/- mice andWT mice indicating that heparanase is not involved
in the recruitment of inflammatory cells to the lung following an acute challenge
with zymosan.
Lipopolysaccharide-induced lung inflammation. The total number of cells in the BAL
fluid of saline injected WTmice (median, 25–75 percentile: 0.92 (0.35 – 1.26) x 106 cells/ml,
n = 5) was predominantly comprised of mononuclear cells and represented 99% of the total
cell population with an absence of neutrophils. There was a tendency (although not statistically
significant) increase in the total number of cells (Fig 2C, p = 0.0652) and a significant increase
in neutrophils (Fig 2D, p = 0.0005) recruited to the airways following challenge with LPS.
There was no significant difference in the number of total cells (Fig 2C) or neutrophils (Fig
2D) between Hpa-/- mice and WTmice indicating that heparanase is not involved in the re-
cruitment of inflammatory cells to the lung following an acute challenge with LPS.
The effect of Muparfostat on non-allergic lung inflammation. The majority of the cells
in the saline treated animals were predominantly comprised of mononuclear cells (> 95%),
but in zymosan vehicle treated animals neutrophils comprised 85% of the total cell number.
Fig 2. The effect of genetic modification of heparanase on neutrophil recruitment to the lung. The total
number of inflammatory cells (A, C) and neutrophils (B, D) recruited to the lung following acute exposure of
wild-type (WT), and Hpa-/- mice to intranasal (i.n.) saline, zymosan (A, B) or LPS (C, D). Data presented as
box plots (median, 25–75 percentile) with whiskers representing 5–95% confidence interval. The number of
animals represented by box plots in each panel is as follows; Panel A, B: Saline treated group (WT; n = nil♀,
5♂; Hpa-/-, n = 2♀, 1♂) and zymosan treated group (WT; n = 4♀, 4♂; Hpa-/-, n = 3♀, 4♂). *p < 0.05
compared with saline; †No significant difference compared with WT zymosan. Panel C, D: Saline treated
group (WT: wild type; n = 2♀, 3♂; Hpa-/-, n = 3♀) and LPS treated group (WT; n = 5♀; Hpa-/-, n = 4♀).
*p < 0.05 compared with saline; †No significant difference compared with WT LPS. Data obtained from
one experiment.
doi:10.1371/journal.pone.0127032.g002
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Treatment of mice with the heparanase inhibitor muparfostat once a day (q.d) or twice a day
(b.i.d) did not significantly alter the total number of inflammatory cells (Fig 3A) or neutrophils
(Fig 3B) infiltrating the lung in response to zymosan.
Similarly, intranasal administration of LPS also caused a significant increase in total cell re-
cruitment to the lung due to the infiltration of neutrophils (80% of total cell count). Muparfo-
stat did not significantly reduce total number of cells (Fig 3C) or neutrophils (Fig 3D) in
response to LPS.
Heparanase expression in human lung tissue
Available clinical data from de-identified healthy and COPD cohorts providing lung tissue are
shown in Table 1. Immunofluorescence revealed that heparanase expression increased with se-
quential increases in GOLD stage (Fig 4, linear trend by ANOVA p = 0.029).
Fig 3. The effect of pharmacological treatment with the heparanase inhibitor Muparfostat on
neutrophil recruitment to the lung. The total number of inflammatory cells (A, C) and neutrophils (B, D)
recruited to the lung following acute exposure to zymosan (A, B) or LPS (C, D). Wild-type (WT), and Hpa-/-
mice received intranasal (i.n.) saline, zymosan (A, B) or LPS (C, D). The number of total cells (A) and
neutrophils (B) in bronchoalveolar lavage fluid 24 h after intranasal administration of zymosan in BALB/c mice
treated with Muparfostat (30 mg/kg s.c.) dosed 30 minutes before (q.d.) and 6 h after (b.i.d) zymosan
exposure, n = 4 per group. Data presented as box plots (median, 25–75 percentile) with whiskers
representing 5–95% confidence interval. *p < 0.05 compared with saline. Data obtained from one
experiment. In other experiments total number of cells (C) and neutrophil (D) recruitment to the lung was
measured following intranasal administration of LPS in vehicle and Muparfostat (b.i.d.) treated mice (n = 3–9).
Data presented as box plots (median, 25–75 percentile) with whiskers representing 5–95% confidence
interval. *p < 0.05 compared with saline. Treatment groups were not significantly different from vehicle
(symbol not reported). Data was obtained from two independent experiments.
doi:10.1371/journal.pone.0127032.g003
Table 1. Patient demographics of COPD patients.
Group Gender (F/M) Age (mean, (SD)) % FEV1 (pre) % FEV1 (post) Pack years
GOLD (0–1) 2/4 56 (8) 89 (78–100) 94 (85–100) 39 (4–74)
GOLD (2) 1/3 51 (6) 48 (38 – 59) 54 (46–63) 30 (-3 – 63)
GOLD (3–4) 2/3 54 (4) 24 (8 – 41) 46 48 (15–81)
% predicted pre and post bronchodilator
Spirometry data not available for healthy donors
doi:10.1371/journal.pone.0127032.t001
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Heparanase plays a role in allergic inflammation
Adult WT mice immunized with OVA and repeatedly exposed to this antigen induced an aller-
gic inflammatory response (Fig 5) characterized by an eosinophilic rich cell infiltrate (42% of
total cells, n = 12). The significant increase in total cells (Fig 5A, p< 0.05), eosinophils (Fig 5B,
p< 0.05) and macrophages (Fig 5C, p< 0.05) following OVA challenge in wild type mice was
inhibited in Hpa-/- mice. Neutrophil and lymphocyte recruitment to the airways were not sig-
nificantly increased following antigen challenge, and the absence of heparanase did not affect
the migration of these cell types into the airways. Th2 cell activation was indirectly assessed by
Fig 4. Heparanase expression in lung tissue from normal subjects and COPD patients of varying
severity. Each point represents the intensity of staining for heparanase expression in normal human lung
tissue and in subjects with varying severities of COPD (A). Representative images are shown (B-F reflecting
Gold 0–1, Gold 2, Gold 3–4, healthy subject, and isotype control, respectively. Red: heparanase; blue: DAPI
(DAPI not performed for isotype control). Image brightness was uniformly adjusted for clarity and all
heparanase quantification was performed using unadjusted (raw) images. Magnification was 40 x for all
images. The data was analyzed as continuous variables and there was a significant linear trend (post-
ANOVA, r-squared = 0.27 and p = 0.029). Horizontal line represents mean and limits represent SEM.
doi:10.1371/journal.pone.0127032.g004
Heparanase and Airway Inflammation
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measurement of OVA specific IgE, which was significantly elevated in WT and Hpa-/- OVA
sensitized and challenged mice compared with their respective controls (Fig 5).
The effect of Muparfostat against OVA induced allergic lung inflammation. Mice treat-
ed with OVA and vehicle showed a significant increase in the total number of cells compared
to sham animals (Fig 6A, p< 0.05). Eosinophils comprised 36% of the total cell infiltrate
Fig 5. Effect of heparanase gene deletion on allergic inflammation induced by ovalbumin (OVA).
Box plots showing (A) total cell, (B) eosinophil, (C) macrophages, (D) lymphocytes, (E) neutrophils in
bronchoalveolar lavage fluid and (F) OVA specific IgE in serum in control and OVA immunized and
challengedmice. Mice were sensitized by repeated i.p. injections with 10 μg OVA or were non-sensitized
(controls). All mice received three i.n. instillations with 20 μg OVA and lavage was undertaken 24 h after the
last intranasal administration of OVA. Data expressed as blox plots (median, 25–75 percentile) with whiskers
representing 5–95% confidence interval (7–12 animals for cell data and 6–10 for IgE data). *p < 0.05
compared with control; †No significant difference compared with Hpa-/- control. Data pooled from four
independent experiments.
doi:10.1371/journal.pone.0127032.g005
Fig 6. Effect of Muparfostat on allergic inflammation induced by OVA. Box plots showing (A) total cell,
(B) eosinophil, (C) mononuclear cell and (D) neutrophil cell number in the lungs of mice following sensitisation
and aerosol challenge with OVA. Mice were treated with Muparfostat (50 mg/kg and 100 mg/kg s.c.) 30
minutes before challenge. Mice were challenged with aerosolised 3%OVA for three consecutive days and
lavage undertaken 24 h after the last challenge. Data expressed as blox plots with whiskers representing
5–95% confidence interval (n = 9–15). *p < 0.05 compared with sham and ‡p < 0.05 compared with vehicle.
Data obtained from four independent experiments.
doi:10.1371/journal.pone.0127032.g006
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(Fig 6B, p< 0.05). In addition, there was also a small and significant increase in the number of
neutrophils and mononuclear cells in the OVA vehicle treated group compared to sham (Fig
6C and 6D). The heparanase inhibitor Muparfostat at the highest dose evaluated caused a sig-
nificant inhibition of eosinophil recruitment to the airways (Fig 6B).
The effect of Muparfostat against OVA induced allergen-induced bronchial hyperre-
sponsiveness. Methacholine caused a dose-dependent increase in post-saline resistance (RL)
(Fig 7A). The percentage increase in post-saline resistance (%RL) of the lungs (i.e. peak re-
sponse) to increasing concentrations of methacholine was significantly greater in OVA vehicle
treated animals compared with sham sensitised animals (mean ± s.e.m; 107.6 ± 16.8, n = 10
versus 213.8 ± 26.4, respectively, n = 11 p< 0.05; Fig 7B). In animals treated with muparfostat
50 mg/kg and 100 mg/kg there was a significant decrease in the peak response (107 ± 10.1,
n = 8, p< 0.01 and 121 ± 21.7, n = 11 p< 0.05 respectively for dose). Similarly, airway sensitiv-
ity to methacholine (RL PC100, mg/mL) was reduced by approximately 3 fold in OVA vehicle
treated animals compared with sham sensitised animals (mean ± s.e.m; 18.5 ± 5.2, n = 10 ver-
sus 49.7 ± 9.5 respectively, n = 10, p< 0.05; Fig 7C) indicating an increase in airway sensitivity
to methacholine. This increase in airway sensitivity was significantly inhibited in OVA sensi-
tized and challenged mice, treated with Muparfostat (50 mg/kg or 100 mg/kg; Fig 7C). The RL
PC100 (mg/mL) was significantly increased compared with vehicle treated sensitized animals
(42 ± 10.2, n = 8 and 47.8 ± 11.5 n = 11, p< 0.05 respectively for dose).
Discussion
Inflammatory cell migration to the lung has a number of similarities with tumour cell metasta-
sis, for example, secreting heparanase to degrade ECM structure. The results demonstrated
that heparanase plays a greater role in regulating the pulmonary cell recruitment of eosinophils
following an allergic, compared with neutrophils following a non-allergic, stimulus.
A previous study has reported that the constitutive cell population within the airways
of mice deficient in heparanase was similar to the number of cells in naïve mice [23], an
observation that was also observed in our study. It has been suggested that the deletion of the
Fig 7. Effect of Muparfostat on OVA induced changes in lung function.Graphs showing (A) % increase
in total lung resistance versus methacholine dose in sham immunized (), OVA sensitized in vehicle-treated
(●) or OVA-immunized mice treated with Muparfostat 50 mg/kg (Mup, □) or Muparfostat 100 mg/kg (Mup, ■) s.
c. before being challenged with aerosolised 3%OVA for 4 consecutive days, (B) peak percentage increase in
post saline resistance, (C) RL provocative concentration (PC)100 for methacholine. Each point or columns
represent mean ± SEM n = 8–11, p < 0.05 versus sham* or vehicle‡. Data obtained from four
independent experiments.
doi:10.1371/journal.pone.0127032.g007
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heparanase gene may lead to a compensatory increase in MMP’s primarily MMP-2, MMP-14
and MMP-9, which are known to degrade the ECM [24], although this is not a consistent find-
ing [17]. Whether compensation by MMPs in the lung could explain why mice deficient in
heparanase were able to recruit neutrophils in response to zymosan or LPS remains to
be established.
We also used a pharmacological approach to inhibit heparanase activity in WT mice using
the heparanase inhibitor, Muparfostat derived from yeast. This phosphosulfomannan has dem-
onstrated efficacy against several cancers in phase I and II clinical trials, either administered
alone or in combination with other therapy [25,26]. Muparfostat inhibits heparanase with an
IC50 of 7.9 nM [27] and has previously been shown to suppress experimental lung metastases
in a B16 melanoma model [28]. However, Muparfostat, in a dose range similar to those re-
ported in this melanoma model did not significantly reduce the number of neutrophils infil-
trating to the lung in response to zymosan or LPS in our study.
The current findings do not support the notion that heparanase is important in the acute in-
nate inflammatory response in response to airway injury, although we have recently reported
that recombinant heparanase is able to promote neutrophil recruitment into tissues [29]. It has
also been reported that heparanase inhibition prevents sepsis-induced mortality and acute lung
injury (ALI) in mice [16]. This apparent discrepancy may reflect pathophysiologic differences
between direct (i.e. intranasal) and indirect (i.e. systemic-induced) lung injury, as suggested by
previously-observed differences in patients with direct (pneumonia) and indirect (sepsis, pan-
creatitis) lung injury [16,30]. Alternatively, heparanase might be important during the early
phase of the inflammatory response, as leukocyte attachment was measured 6 h after acute
lung injury [16] whilst in our studies we measured leukocyte recruitment at a 24 h time point.
It has recently been shown that heparanase is involved in the chronic inflammatory re-
sponse in ulcerative colitis [31] and chronic inflammation is known to have a profound effect
on tumour progression [32]. Consequently, heparanase is a potential target for therapeutic in-
tervention in chronic inflammatory disease states. We investigated the expression of hepara-
nase in subjects with different severities of COPD and found an association of heparanase
expression in lung tissue and COPD severity. This would be consistent with evidence of in-
creased expression of this enzyme in other chronic inflammatory conditions including protei-
nuric disease [33], chronic haemodialysis [34], rheumatoid arthritis [13], Crohn’s disease and
ulcerative colitis but not in infection colitis [12]. We cannot draw any conclusion concerning
cause and effect, but our data highlight a further avenue for research regarding the role of
heparanase in COPD.
Whilst mice deficient in heparanase have been shown to have no detectable difference in re-
sponse to a DTH reaction [24], although there was a reduction in the number of monocytes re-
cruited to the inflammatory site [15], a pharmacological approach using the in vivo
administration of anti-heparanase siRNA or an inhibitor of heparanase enzymatic activity ef-
fectively abolished the DTH inflammatory response in the skin of mice [14]. Hence, we investi-
gated the role of heparanase in allergic inflammation in the lung using an allergic model of
murine lung inflammation which is characterized by a Th2 phenotype [35]. Mice sensitized
and then exposed to aerosolized OVA demonstrated a significant increase in inflammatory cell
influx, predominantly composed of eosinophils which was accompanied with changes in pul-
monary lung mechanics, as evident by an increase in airways responsiveness to methacholine.
We have demonstrated significantly lower number of eosinophils in the BAL fluid of Hpa-/-
mice sensitized and then subsequently challenged with ovalbumin. This is consistent with a re-
port demonstrating that the ablation of heparanase attenuated eosinophil recruitment and Th2
cytokine response in house dust mite immunized mice [17]. This effect of heparanase is further
demonstrated following pharmacological treatment of mice with a heparanase inhibitor.
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Moreover, we for the first time have demonstrated bronchial hyperresponsiveness (BHR) was
suppressed following pharmacological inhibition of heparanase. To increase the generality of
our findings we used two different strains of mice for studies on the role of heparanase in pul-
monary allergic inflammation. Strain dependent differences in bronchial hyperresponsiveness
following antigen challenge are well known [36] and the BALBc strain is more sensitive than
C57Bl/6 strain for measuring physiological changes in respiratory lung mechanics.
There are a number of possible mechanisms to explain the decrease in eosinophil recruit-
ment to the lung and the reduction of BHR following inhibition of heparanase. We and others
have demonstrated that platelets are central to the recruitment of eosinophils in allergic inflam-
mation [37–39]. In addition, activated, but not resting platelets were also necessary for the de-
velopment of leukocyte complexes and the subsequent inflammatory response [40]. Platelet
secreted heparanase [41] affects various signal transduction pathways following uptake into
cells [42]. Other cell types involved in the allergic inflammatory response in the airways includ-
ing dendritic cells [17,43], T cells [44–50] and vascular endothelium [16,50,51] also express
heparanase to potentially regulate the migration of leukocytes to sites of inflammation. Selec-
tive ablation of heparanase in individual cell types would be required to investigate the role of
heparanase expressing cells in the allergic inflammatory response and is beyond the scope of
this study.
Conclusions
We have demonstrated a role for heparanase in acute allergic inflammation, in the lung and
our findings highlight a potential role for this enzyme in cell recruitment to the airways and
that targeting heparanase may be beneficial in the treatment of allergic pulmonary diseases.
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